comparemela.com

Latest Breaking News On - Clinical update - Page 1 : comparemela.com

Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,.

United statesStacy nartkerWildon farwellAmy reillyJohn coxExchange commissionDrug administrationMyotonic dystrophy health indexEuropean medicines agencyDyne therapeutics incDose dependentMean splicing correction across all patientsMuscle strengthTimed function testsReported outcomesMean unadjusted

Dyne Therapeutics Announces New Clinical Data from ACHIEVE

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - .

United statesAmy reillyJohn coxStacy nartkerWildon farwellExchange commissionDyne therapeutics incEuropean medicines agencyDrug administrationMyotonic dystrophy health indexDose dependentMean splicing correction across all patientsMuscle strengthTimed function testsReported outcomesMean unadjusted

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Todd foleyStevenh steinLloydm segalBristol myers squibbRepare therapeutics incEuropean society of medical oncologyIncyte corporationCompany quarterly report on formDrug administrationCompany nasdaqExchange commissionGastrointestinal gi cancers congressModule of the company phaseTherapeutics provides businessClinical updateReports first quarter

Destigmatizing Personality Disorders

Don't miss these 2 APA Annual Meeting sessions on personality disorders!

United statesAmerican psychiatric association annual meetingJavits centerPsychiatric association annual meetingClinical updatePersonality disordersPersonality pathology

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes At Week 26, 22 weeks after the last dose of BMF-219,.

United statesExchange commissionSecurities exchangeClinical updateMultiple ascending doseGlycemic dataPharmacokinetic dataEx vivo human islet dataSecurities actSecurities exchange actExchange actBiomea fusion

vimarsana © 2020. All Rights Reserved.